Copeptin for Prediction of Treatment Response in Children With Monosymptomatic Nocturnal Enuresis (MEN).

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT02621736

Acronym

COMEN

Enrollment

Registered

2015-12-03

Start date

2016-01-01

Completion date

2021-06-30

Last updated

2021-12-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Nocturnal Enuresis

Keywords

children, desmopressin, copeptin

Brief summary

Monosymptomatic nocturnal enuresis (MEN) is a common problem in children, affecting 7-10% of all 7 year olds. MEN is often leading to psychosocial problems because of its burden and stigmatism. The only available medical treatment option is the vasopressin analogum Desmopressin®. However, according to the literature, only one third of patients shows a good treatment response, defined as more than 90% of reduced bed wetting. Furthermore, treatment with Desmopressin® may lead to psychosocial problems, high costs and potentially dangerous side effects like water intoxication and hypertension. Copeptin, mirroring arginine vasopressin (AVP), has been shown to be significantly lower in patients with MEN compared to controls and lower in patients with severe bed wetting compared to patients with only slight bed wetting.

Interventions

OTHERblood sampling

At 4 visits capillary blood sampling for copeptin measurement will be performed with each child.

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

5 Years to 16 Years

Healthy volunteers

Inclusion criteria

* Children at the age between 5 and 16 years * Diagnosis of monosymptomatic nocturnal enuresis * Completion of uroflowmetry and bladder sonography if possible * Completion of home recording charts of bed wetting episodes if possible * Willingness to use Desmopressin® treatment

Exclusion criteria

* Children with daytime enuresis * Children with lower urinary tract symptoms and infection * Children with structural abnormalities of the urinary tract * Children with chronic illness, esp. renal failure, hypertension, congenital heart disease, diabetes mellitus and diabetes insipidus.

Design outcomes

Primary

Measure	Time frame
Change of copeptin at baseline and after 28 days during routine desmopressin therapy	morning and evening copeptin levels at baseline day 0 before routine desmopressin therapy and day 28 during routine desmopressin therapy

Countries

Switzerland

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026